Roche lends weight to Swiss biotech; Regeneron makes genomic headway;

@FierceBiotech: Astellas backs out of a $760M Alzheimer's deal with CoMentis. Item | Follow @FierceBiotech

@JohnCFierce: This low-T field is definitely starting to look like the slum area of R&D. | Follow @JohnCFierce

@DamianFierce: Early look at Adaptimmune's cancer immunotherapy data: 1 complete response and 3 partials among 5 patients. Story | Follow @DamianFierce

@EmilyMFierce:  The

> Roche ($RHHBY) is teaming up with Swiss biotech Cardiorentis, lending diagnostic know-how as the company works through a Phase III trial of an acute heart failure treatment. More

> Pharmacyclics ($PCYC) has signed a deal with to study its Johnson & Johnson ($JNJ)-partnered cancer treatment in tandem with Roche's ($RHHBY) Gazyva. News

> Regeneron ($REGN) is moving forward with its wholly owned genetics lab, sequencing about 10,000 genomes and striking collaboration with Columbia University, Baylor and others. Release

Medical Device News

@FierceMedDev: Medical device venture deals pull in more money per deal. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Stryker scores with Q3 earnings, beating the Street's expectations and posting $2.39B in revenue. Article | Follow @EmilyWFierce

@MichaelGFierce: Stealthy, DNA-based 'nano-cocoons' deliver #cancer-killing payloads. News | Follow @MichaelGFierce

> Former GE Healthcare head John Dineen joins private equity group. More

> Stryker to repatriate $2B, ready for acquisitions in 2H15. Story

> Boston Scientific wins CE mark for MRI-friendly pacemaker products. News

Pharma News

@FiercePharma: Tops in FierceVaccines Thurs: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. Story | Follow @FiercePharma

@EricPFierce: I suspect Laura Schumacher spent late nights as AbbVie board decided whether to walk away from Shire deal. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. Subscribe here to get it weekly. Subscribe | Follow @CarlyHFierce

> Lilly will close Puerto Rico plant affecting 100 workers. Article

> FDA says Pfizer's Chantix must continue to wear a 'black box' label. Story

> AbbVie's $1.635B breakup fee to Shire, if paid, will run third highest ever. Item

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.